300972 Stock Overview
Fujian Wanchen Biotechnology Co., Ltd engages in the research and development, cultivation, production, and sale of edible fungi in China.
Snowflake Score | |
---|---|
Valuation | 3/6 |
Future Growth | 6/6 |
Past Performance | 0/6 |
Financial Health | 5/6 |
Dividends | 0/6 |
Fujian Wanchen Biotechnology Group Co., Ltd. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | CN¥25.86 |
52 Week High | CN¥40.70 |
52 Week Low | CN¥17.69 |
Beta | -0.018 |
11 Month Change | 28.34% |
3 Month Change | -5.96% |
1 Year Change | -36.82% |
33 Year Change | 63.98% |
5 Year Change | n/a |
Change since IPO | -5.27% |
Recent News & Updates
Shareholder Returns
300972 | CN Food | CN Market | |
---|---|---|---|
7D | 27.4% | -2.2% | -0.3% |
1Y | -36.8% | -19.8% | -18.1% |
Return vs Industry: 300972 underperformed the CN Food industry which returned -19.8% over the past year.
Return vs Market: 300972 underperformed the CN Market which returned -18.1% over the past year.
Price Volatility
300972 volatility | |
---|---|
300972 Average Weekly Movement | 8.3% |
Food Industry Average Movement | 4.7% |
Market Average Movement | 5.6% |
10% most volatile stocks in CN Market | 8.9% |
10% least volatile stocks in CN Market | 3.7% |
Stable Share Price: 300972's share price has been volatile over the past 3 months.
Volatility Over Time: 300972's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of CN stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2011 | 4,972 | Li Qing Wang | www.vanchen.com |
Fujian Wanchen Biotechnology Co., Ltd engages in the research and development, cultivation, production, and sale of edible fungi in China. It offers flammulina velutipes; and crab-flavored, white jade, seafood mushrooms, etc. The company was founded in 2011 and is based in Zhangpu, China.
Fujian Wanchen Biotechnology Group Co., Ltd. Fundamentals Summary
300972 fundamental statistics | |
---|---|
Market cap | CN¥4.58b |
Earnings (TTM) | -CN¥76.42m |
Revenue (TTM) | CN¥17.99b |
0.3x
P/S Ratio-60.0x
P/E RatioIs 300972 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
300972 income statement (TTM) | |
---|---|
Revenue | CN¥17.99b |
Cost of Revenue | CN¥16.19b |
Gross Profit | CN¥1.80b |
Other Expenses | CN¥1.88b |
Earnings | -CN¥76.42m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -0.43 |
Gross Margin | 10.03% |
Net Profit Margin | -0.42% |
Debt/Equity Ratio | 89.8% |
How did 300972 perform over the long term?
See historical performance and comparison